Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

NCT04189614 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04189614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
February 13, 2020
Completion date
May 7, 2026
Enrollment
65 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, non-small cell lung cancer (nsclc)